The 6-Aminoquinolone WC5 Inhibits Human Cytomegalovirus Replication at an Early Stage by Interfering with the Transactivating Activity of Viral Immediate-Early 2 Protein
- 1 May 2010
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (5) , 1930-1940
Abstract
WC5 is a 6-aminoquinolone that potently inhibits the replication of human cytomegalovirus (HCMV) but has no activity, or significantly less activity, against other herpesviruses. Here we investigated the nature of its specific anti-HCMV activity. Structure-activity relationship studies on a small series of analogues showed that WC5 possesses the most suitable pattern of substitutions around the quinolone scaffold to give potent and selective anti-HCMV activity. Studies performed to identify the possible target of WC5 indicated that it prevents viral DNA synthesis but does not significantly affect DNA polymerase activity. In yield reduction experiments with different multiplicities of infection, the anti-HCMV activity of WC5 appeared to be highly dependent on the viral inoculum, suggesting that WC5 may act at an initial stage of virus replication. Consistently, time-of-addition and time-of-removal studies demonstrated that WC5 affects a phase of the HCMV replicative cycle that precedes viral DNA synthesis. Experiments to monitor the effects of the compound on virus attachment and entry showed that it does not inhibit either process. Evaluation of viral mRNA and protein expression revealed that WC5 targets an event of the HCMV replicative cycle that follows the transcription and translation of immediate-early genes and precedes those of early and late genes. In cell-based assays to test the effects of WC5 on the transactivating activity of the HCMV immediate-early 2 (IE2) protein, WC5 markedly interfered with IE2-mediated transactivation of viral early promoters. Finally, WC5 combined with ganciclovir in checkerboard experiments exhibited highly synergistic activity. These findings suggest that WC5 deserves further investigation as a candidate anti-HCMV drug with a novel mechanism of action.Keywords
This publication has 39 references indexed in Scilit:
- A 6-Aminoquinolone Compound, WC5, with Potent and Selective Anti-Human Cytomegalovirus ActivityAntimicrobial Agents and Chemotherapy, 2009
- New cell-based indicator assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral immediate-early 2 protein activityJournal of Applied Microbiology, 2008
- Phosphorothioate-Modified Oligodeoxynucleotides Inhibit Human Cytomegalovirus Replication by Blocking Virus EntryAntimicrobial Agents and Chemotherapy, 2008
- Human cytomegalovirus DNA replication: antiviral targets and drugsReviews in Medical Virology, 2007
- Binding parameters and thermodynamics of the interaction of the human cytomegalovirus DNA polymerase accessory protein, UL44, with DNA: implications for the processivity mechanismNucleic Acids Research, 2007
- Virucidal Activity of a GT-Rich Oligonucleotide against Herpes Simplex Virus Mediated by Glycoprotein BJournal of Virology, 2006
- Selective Anti-Cytomegalovirus Compounds Discovered by Screening for Inhibitors of Subunit Interactions of the Viral PolymeraseChemistry & Biology, 2006
- The Putative Zinc Finger of the Human Cytomegalovirus IE2 86-Kilodalton Protein Is Dispensable for DNA Binding and Autorepression, Thereby Demarcating a Concise Core Domain in the C Terminus of the ProteinJournal of Virology, 2004
- Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real‐time quantitative DNA PCR assay: Correlation with pp67 RNA detectionJournal of Medical Virology, 2004
- Inhibition of Human Cytomegalovirus DNA Polymerase by C-Terminal Peptides from the UL54 SubunitJournal of Virology, 2003